 |
인쇄하기
취소
|
Three drug makers to be contested in domestic hepatitis B market
Domestic hepatitis B market will emerge as an arena of tripartite competition - GlaxoSmithKline's Zeffix (lamivudine) and Hepsera (adefovir), Bukwang Pharm's Levovir (clevudine) and BMS Korea's Baraclude (entecavir).
The debut of Levovir and Baraclude is expected to change the map of the hepatitis B drug market dominated by GSK.
An official at Bukwang Pharm said that as its marketing str...
The debut of Levovir and Baraclude is expected to change the map of the hepatitis B drug market dominated by GSK.
An official at Bukwang Pharm said that as its marketing str...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.